Uncontrolled cell growth within a tumor results in hypoxia as the metabolic needs of the cells exceed the ability of the tumor vasculature to provide oxygen and nutrients. In response to the hypoxic microenvironment, cells undergo a massive reprogramming of transcription to promote survival. The Hypoxia Inducible Transcription Factors (HIFs) are primary regulators of the hypoxic response and induce the expression of glycolytic genes, cell migration factors, and angiogenic factors. HIFs also induce expression of several transcriptional regulators, including several histone demethylases, providing a mechanism for the hypoxic cell to extend or fix the expression of pro-survival genes. One of these histone demethylases, JMJD2B, demethylates tri-methylated histone H3 lysine 9 (H3K9me3), a key marker of repressed chromatin structure. Hypoxic induction of JMJD2B may play an important role in activating gene expression to promote tumor growth. Consistent with this hypothesis, forced knock-down of JMJD2B expression reduces growth of tumor xenografts, and is overexpressed in ovarian cancers. In this proposal, the extent to which JMJD2B regulates tumor growth will be tested in vivo using tumor xenograft experiments and in vitro by assaying for cell proliferation, invasion, and angiogenesis as a result of JMJD2B expression (Specific Aim 1). Subsequent biochemical experiments will determine the mechanism of specific target gene regulation in hypoxia, identify new genes regulated by JMJD2B in hypoxia, and characterize the regulation of key pathways of genes important for the tumorigenic phenotype (Specific Aim 2). The experiments described in this proposal will establish the mechanisms utilized by JMJD2B to regulate tumorigenesis, while identifying new pathways to target for enhanced tumor therapies.
Cancer cells typically grow faster than the surrounding blood vessels can supply oxygen and nutrients. In response to decreased oxygen (hypoxia), cancer cells alter their gene expression to enhance survival, resulting in more aggressive tumors. In this study we will determine the function of JMJD2B, a regulator of hypoxic gene expression in cancer cells, with the ultimate goal of finding better targets for cancer therapy.
|Wang, Huizhen; Luo, Jinping; Carlton, Carol et al. (2017) Sperm-oocyte contact induces outside-in signaling via PYK2 activation. Dev Biol 428:52-62|
|Padró, Mercè; Louie, Raymond J; Lananna, Brian V et al. (2017) Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells. BMC Cancer 17:203|
|New, Jacob; Arnold, Levi; Ananth, Megha et al. (2017) Secretory Autophagy in Cancer-Associated Fibroblasts Promotes Head and Neck Cancer Progression and Offers a Novel Therapeutic Target. Cancer Res 77:6679-6691|
|Rogers, Robert S; Tungtur, Sudheer; Tanaka, Tomohiro et al. (2017) Impaired Mitophagy Plays a Role in Denervation of Neuromuscular Junctions in ALS Mice. Front Neurosci 11:473|
|Lui, Asona J; Geanes, Eric S; Ogony, Joshua et al. (2017) IFITM1 suppression blocks proliferation and invasion of aromatase inhibitor-resistant breast cancer in vivo by JAK/STAT-mediated induction of p21. Cancer Lett 399:29-43|
|Tan, Ee Phie; Duncan, Francesca E; Slawson, Chad (2017) The sweet side of the cell cycle. Biochem Soc Trans 45:313-322|
|Wilson, C; Qiu, L; Hong, Y et al. (2017) The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer. Oncogene 36:2565-2576|
|Chen, Lei; Zhao, Lin; Samanta, Anweshan et al. (2017) STAT3 balances myocyte hypertrophy vis-à-vis autophagy in response to Angiotensin II by modulating the AMPK?/mTOR axis. PLoS One 12:e0179835|
|Jasti, Susmita; Farahbakhsh, Mina; Nguyen, Sean et al. (2017) Immune response to a model shared placenta/tumor-associated antigen reduces cancer risk in parous mice. Biol Reprod 96:134-144|
|Samanta, Saheli; Rajasingh, Sheeja; Cao, Thuy et al. (2017) Epigenetic dysfunctional diseases and therapy for infection and inflammation. Biochim Biophys Acta 1863:518-528|
Showing the most recent 10 out of 58 publications